J&J Backs Another Round of Philadelphia Companies Through Health Equity Innovation Challenge

Published on : Published by : Alex Keown

The challenge provides financial support and mentorship to selected organizations making a key difference through innovative solutions that seek to reduce the inequities among these communities. The latest J&J Health Equity Innovation Challenge recipients in Philadelphia are eCLOSE Institute, which is inspiring diversity in science through STEM education and job training for students from under-resourced schools; Maternity Care Coalition, an organization focused on reducing infant mortality rates among minority communities through its Perinatal Community Health Worker Program that has trained more than 200 perinatal community health workers; and tech startup Viora Health, which is creating a personalized engagement solution to address social and behavioral determinants for conditions like pre-diabetes, diabetes and obesity, all indications that overwhelmingly impact communities of color.

IndyGeneUS AI and the Blockchain-Secured Genomic Data Marketplace

Published on : Published by : Alex Keown

IndyGeneUS AI and the Blockchain-Secured Genomic Data Marketplace IndyGeneUS AI, which is harnessing the power of data mining and artificial intelligence to expedite the development and manufacturing of targeted therapeutics, [….]

Regional Collaborations Emerge to Address the Biomanufacturing Workforce Crisis

Published on : Published by : Steven Surdez

We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.

COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization

Published on : Published by : BioBuzz Media

Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and have been authorized as part of Johnson & Johnson’s Emergency Use Authorization (EUA).

Novavax trials highlight Maryland’s COVID-fighting complex

Published on : Published by : BioBuzz Media

Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]

Emergent Rallies to Meet COVID-19 Vaccine Supply Challenge

Published on : Published by : Alex Keown

Emergent BioSolutions’ contract development and manufacturing (CDMO) business is playing a crucial role in supporting the battle against COVID-19. The company has contracted with multiple vaccine makers, including AstraZeneca and Johnson & Johnson, to manufacture the preventative medications.

5 Questions with Rachel Rath, MBA, MPH, Director, BARDA Alliance for Johnson & Johnson Innovation, JLABS @ Washington, DC

Published on : Published by : Andy Eckert

Rachel is the Director of the BARDA Alliance for Johnson & Johnson Innovation, based at JLABS @ Washington, DC. In this role, she is responsible for managing the BLUE KNIGHT™ collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). BLUE KNIGHT™ focuses on addressing public-health threats and emerging infectious diseases by supporting companies with emerging science and technology solutions that aim to improve health security and responses.

Five Companies Edging Closer to SARS-CoV-2 Vaccine Emergency Use Authorization

Published on : Published by : Steven Surdez

Global COVID-19 cases have been spiking in Europe and the U.S. as the predicted second wave is hitting communities hard, applying new pressure on hospital capacity and forcing local and state governments to once again tighten restrictions.